Bionomics (NASDAQ:BNOX) Earns Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Bionomics (NASDAQ:BNOX) in a report released on Thursday morning, Benzinga reports. They currently have a $8.00 target price on the stock.

Bionomics Stock Performance

Shares of BNOX traded down $0.06 during trading hours on Thursday, hitting $0.51. 230,971 shares of the company were exchanged, compared to its average volume of 522,941. Bionomics has a fifty-two week low of $0.50 and a fifty-two week high of $6.41. The firm’s fifty day moving average is $0.76 and its 200 day moving average is $0.94.

Bionomics Company Profile

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.